Nova Pharmaceuticals

Nova Pharmaceuticals is a clinical-stage biotechnology company focused on targeting the molecular mechanisms that cause triple-negative and metaplastic breast cancer to develop resistance to current treatments, with the aim of improving patient outcomes. Nova Pharmaceuticals' pan-nitric oxide synthase (NOS) inhibitor is currently in Phase 1/2 studies at Houston Methodist Hospital and has completed a Phase 1/2 study in patients with triple-negative breast cancer.